| Drug Type Small molecule drug | 
| Synonyms NAV2729 | 
| Target | 
| Action inhibitors | 
| Mechanism ARF6 inhibitors(ADP ribosylation factor 6 inhibitors) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Ovarian Cancer | Preclinical | Austria  | 05 Dec 2022 | |
| Triple Negative Breast Cancer | Preclinical | United States  | 01 Dec 2022 | |
| Inflammation | Preclinical | - | 30 Nov 2022 | |
| COVID-19 | Preclinical | - | 21 Nov 2022 | |
| Uveal Melanoma | Preclinical | United States  | 02 Jun 2016 | |
| Uveal Melanoma | Preclinical | United States  | 02 Jun 2016 | |
| Uveal Melanoma | Preclinical | United States  | 02 Jun 2016 | |
| Uveal Melanoma | Preclinical | United States  | 02 Jun 2016 | 





